ORIGINAL RESEARCH article
Front. Nutr.
Sec. Clinical Nutrition
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1650337
This article is part of the Research TopicThe Role of Nutrition in Enhancing Surgical Recovery and OutcomesView all 4 articles
Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of neoadjuvant immunochemotherapy in Esophageal Squamous Cell Carcinoma
Provisionally accepted- Affiliated Hospital of North Sichuan Medical College, Nanchong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Sarcopenia is a systemic disorder characterized by the progressive loss of skeletal muscle mass and function; however, its impact on the treatment outcomes of patients with esophageal cancer remains inconclusive. We aimed to evaluate the impact of sarcopenia and dynamic changes in skeletal muscle during treatment on neoadjuvant immunochemotherapy (NICT) efficacy and prognosis in patients with locally advanced ESCC.Methods: We retrospectively included 272 patients with locally advanced ESCC who received NICT. We calculated the skeletal muscle index (SMI) and its rate of change (ΔSMI%) from CT images at the L3 vertebral level obtained before and after treatment. Sarcopenia was defined as an SMI < 52.4 cm²/m² in men and < 38.5 cm²/m² in women, and a ΔSMI% < -2.8% was designated as excessive skeletal muscle loss.Results: The prevalence of sarcopenia increased from 50.9% before treatment to 55.1% at therapy completion. Pre-NICT sarcopenia correlated with tumor progression (P = 0.02) and was associated with a significantly lower pathological complete response (pCR) in patients who had sarcopenia than in those without (14.7% vs 25.0%, P = 0.04). Patients with tumor progression had a significantly lower SMI than those in the disease-control group (41.6 ± 7.24 vs 48.71 ± 8.39, P = 0.04). In a subgroup analysis of excessive skeletal muscle loss, these patients experienced higher hematologic toxicity (leukopenia: 33.4% vs 20.9%, P = 0.04; anemia: 70.7% vs 50.6%, P = 0.01) and lower pCR rate (12.0% vs 22.8%, P = 0.05). After a median follow-up of 20.4 months, sarcopenia before or after NICT did not significantly affect overall survival (OS) or disease-free survival (DFS) (P > 0.05). Conversely, excessive skeletal muscle loss during treatment emerged as an independent prognostic factor for OS in multivariate analysis (HR = 0.47; 95 % CI, 0.25-0.91; P = 0.03); however, it was not associated with DFS (P = 0.22).Conclusion: Treatment-induced excessive skeletal muscle loss may serve as a predictive marker for NICT toxicity and short-term survival in patients with locally advanced ESCC, highlighting the need for dynamic nutritional monitoring to optimize treatment tolerance.
Keywords: Sarcopenia, Skeletal muscle index, esophageal squamous cell carcinoma, Neoadjuvant immunochemotherapy, overall survival
Received: 19 Jun 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Xu, Liu, Zhang, Luo, Xiong, Wang, Shi and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Binwen Xu, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
Maoyong Fu, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.